Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point‐of‐care quantitative test with two established ELISA assays
J. Afonso, S. Lopes, R. Gonçalves, P. Caldeira, P. Lago, H. Sousa, J. Ramos, A. Gonçalves, P. Ministro, I. Rosa, A. Vieira, C. Dias, F. Magro•October 1, 2016•57 citations
Chat with this paper
Extract insights, manage references, and accelerate your research
Continue your research
– It's free
Abstract
The Quantum Blue IFX assay can successfully replace the commonly used ELISA-based IFX quantification kits. This point-of-care IFX assay is able to deliver the results within 15 min makes it ideal for an immediate target concentration adjusted dosing. Moreover, it is a user-friendly desktop device that does not require specific laboratory facilities or highly specialised personnel.